Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stacofylline is a trimethylxanthine derivative and potent acetylcholinesterase (AChE) inhibitor with an IC50 of 5-50 nM. It was investigated for potential antimigraine characteristics and cognitive disorders. In experimental studies, S9977 demonstrated moderate hypotensive and bradycardic effects, with decreased carotid blood flow at higher doses. Unlike dihydroergotamine, its effects appeared related to decreased arterial blood pressure rather than active vasoconstriction of arteriovenous anastomoses. The compound was also studied comparatively with tacrine for effects on psychomotor activity and passive avoidance in cognitive disorder models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stacofylline.